Teleradiology Solutions

telradsol.com →

+2%

est. 2Y upside i

HealthcareSeries D+

Rank

#3574

Sector

Healthcare Services

Est. Liquidity

~4Y

Data Quality

Data: Low

Teleradiology Solutions is a 24-year-old company generating only $14M in revenue despite Bessemer Venture Partners backing — a stark mismatch that indicates the original growth thesis has not materialized and the company has reached a plateau in a competitive, increasingly AI-disrupted market.

Last updated: May 5, 2026

Bull (15%)+85%

A $168B TAM growing at 27% YoY and the proprietary RADSpa platform attract a strategic acquirer — a large US health system or radiology group — at 5–6x revenue, implying a ~$70–85M valuation and roughly 85% upside on current equity grants. This requires meaningful revenue acceleration from the current $14M base and an M&A event materializing within the 2-year horizon.

Base (50%)+10%

Slow organic growth pushes revenue to ~$16–17M over two years, but without a clear exit catalyst the company continues operating privately in its niche; an eventual transaction at ~2.5x revenue (~$40M) or indefinite continuation as a profitable services firm yields only ~10% equity return. No IPO signals exist in the data.

Bear (35%)-45%

Better-capitalized US competitors (Radiology Partners, vRad) and emerging AI-assisted radiology reading commoditize the core service; 24 years of operation with only $14M in revenue demonstrates a structural ceiling on growth, and a down-round, distressed sale, or equity write-down produces a ~45% loss on grant value with no near-term liquidity path.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Funding Intensity

0%

Total funding is undisclosed; with Bessemer Venture Partners as lead investor across what is almost certainly multiple rounds over a 24-year history, preferred liquidation preferences likely represent a meaningful dollar overhang above common stock, but exact amounts cannot be quantified from available data.

Dilution Risk

high

A VC-backed company operating for 24 years has almost certainly completed multiple financing rounds, creating significant cumulative dilution for common shareholders that is impossible to size without cap table disclosure.

Secondary Liquidity

none

No secondary market activity is evident for this private, India-headquartered company with no disclosed IPO signals or secondary transaction history.

Questions to Ask at the Interview

Strategic questions based on Teleradiology Solutions's data — designed to show you've done your homework.

  • 1

    “What is the current post-money valuation and cap table structure — specifically how much in liquidation preferences sits above common stock, and has the company ever done a down-round?”

  • 2

    “What has been the actual revenue CAGR over the last three years, and how does RADSpa's win rate in competitive RFPs compare against vRad and Radiology Partners on US contracts?”

  • 3

    “What is the board's explicit path to liquidity — strategic sale, IPO, or indefinite private operation — and on what timeline, given the company has been operating for 24 years without a public exit?”

Community

Valuation Sentiment

Our model estimates +2% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.